AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.

[1]  A. Doré,et al.  Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain , 2014, Nature.

[2]  Yi Jin,et al.  Metabolism and Disposition of the Metabotropic Glutamate Receptor 5 Antagonist (mGluR5) Mavoglurant (AFQ056) in Healthy Subjects , 2013, Drug Metabolism and Disposition.

[3]  W. Spooren,et al.  CTEP: A Novel, Potent, Long-Acting, and Orally Bioavailable Metabotropic Glutamate Receptor 5 Inhibitor , 2011, Journal of Pharmacology and Experimental Therapeutics.

[4]  F. Nicoletti,et al.  Metabotropic glutamate receptors: From the workbench to the bedside , 2011, Neuropharmacology.

[5]  V. Mutel,et al.  mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents. , 2011, Current topics in medicinal chemistry.

[6]  Janice Branson,et al.  Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056 , 2011, Science Translational Medicine.

[7]  E. Altmann,et al.  1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists. , 2010, Journal of medicinal chemistry.

[8]  J. Deschamps,et al.  Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists. , 2009, Journal of medicinal chemistry.

[9]  Baltazar Gomez-Mancilla,et al.  mGluR5 antagonists: discovery, characterization and drug development. , 2008, Current opinion in drug discovery & development.

[10]  A. Mutlib,et al.  Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. , 2007, Bioorganic & medicinal chemistry letters.

[11]  W. Guba,et al.  Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists. , 2007, Bioorganic & medicinal chemistry letters.

[12]  S. Mickel,et al.  Broad Spectrum Chemistry as Practised by Novartis Process Research , 2004 .

[13]  Mark Washburn,et al.  3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. , 2003, Journal of medicinal chemistry.

[14]  M. Bradbury,et al.  Reduced stress‐induced hyperthermia in mGluR5 knockout mice , 2002, The European journal of neuroscience.

[15]  G. Nowak,et al.  Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats , 2002, Neuropharmacology.

[16]  Fabrizio Gasparini,et al.  [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. , 2002, Bioorganic & medicinal chemistry letters.

[17]  W. Spooren,et al.  Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). , 2002, European journal of pharmacology.

[18]  W. Spooren,et al.  Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. , 2000, The Journal of pharmacology and experimental therapeutics.

[19]  F. Gasparini,et al.  The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors* , 2000, The Journal of Biological Chemistry.

[20]  H. Diener,et al.  Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist. , 2000, Stroke.

[21]  Roland Heckendorn,et al.  2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.

[22]  F. Gasparini,et al.  SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. , 1999, The Journal of pharmacology and experimental therapeutics.

[23]  F. Gasparini,et al.  CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. , 1999, Molecular pharmacology.

[24]  Berend Olivier,et al.  Stress-Induced Hyperthermia in Singly Housed Mice , 1997, Physiology & Behavior.

[25]  T. Knöpfel,et al.  A Novel Splice Variant of a Metabotropic Glutamate Receptor, Human mGluR7b , 1997, Neuropharmacology.

[26]  A. Young,et al.  Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5 , 1995, Neuropharmacology.

[27]  T. Knöpfel,et al.  Molecular Cloning, Functional Expression and Pharmacological Characterization of the Human Metabotropic Glutamate Receptor Type 2 , 1995, The European journal of neuroscience.

[28]  J. Grotta,et al.  Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. , 1995, Stroke.

[29]  T. Knöpfel,et al.  Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 4 , 1995, Neuropharmacology.

[30]  Josemir W Sander,et al.  The excitatory amino acid antagonist d-CPP-ene (SDZ EAA-494) in patients with epilepsy , 1993, Epilepsy Research.

[31]  Daniela Berg,et al.  Treatment of Levodopa-Induced Dyskinesias : Results of 2 Randomized Controlled Trials , 2011 .

[32]  J. E. Dolfini,et al.  Aziridinyl compounds as intermediates in pyrrolidine synthesis. , 1965, Tetrahedron letters.